Brainomix Partners with TIPAL Trial to Assess Its Novel IPF Biomarker in Lung Disease.

Professor Andrew Wilson, TIPAL Chief Investigator, said "It is great to have the chance to incorporate the cutting-edge CT scanning technology developed by Brainomix into the TIPAL study. Keywords: Antiulcer Agents; Biomarkers; Brainomix; Diagnostics and Screening; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Lansoprazole Therapy; Pharmaceuticals; Proton Pump Inhibitors; Technology EN Antiulcer Agents Biomarkers Brainomix Diagnostics and Screening Drugs and Therapies Gastrointestinal Agents Health and Medicine Lansoprazole Therapy Pharmaceuticals Proton Pump Inhibitors Technology 284 284 1 09/19/23 20230919 NES 230919 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Brainomix announced that they will be partnering with the TIPAL trial group to run a sub-study to assess the efficacy of its groundbreaking e-Lung platform. [Extracted from the article]

Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)